In the past decade, many new treatments for migrainous headache have been developed and marketed. The flow has slowed up in the past year or two, not least because several good theoretical ideas have not proved valuable in clinical practice, and the comprehensive review of current drugs is therefore timely. Professor Christopher Diener, who has published distinguished research on the pathophysiology of headache as well as its treatment, has assembled a panel of authorities to …